Skip to content
Screener

Acadia Pharmaceuticals ACAD Daybue — Revenue

Other product segments

Nuplazid
$183.13M+8.7%

Similar metrics at other companies

HRO
HROWOther Revenues — Revenue
$73K-15.1%
Oracle logo
ORCLCloud Revenues — Revenue
$9.91B+47.1%
Oracle logo
ORCLSoftware Revenues — Revenue
$6.82B-2.1%
Blue Owl Capital logo
OWLPerformance revenues — Revenue
$6.07M-3.9%
EAT
EATFranchise revenues — Revenue
$14.7M+21.5%
Cinemark Holdings logo
CNKOther Revenues — Revenue
$113.1M+18.2%

Other financials

Income statement

See full
Revenue$308.0M+16.4%
Gross profit$279.6M+14.7%
Operating income$37.8M+16.9%
Net income$31.5M+18.1%
EPS (diluted)$0.18+12.5%

Balance sheet

See full
Cash & equivalents$385.0M+51.8%
Total debt$73.9M+31.2%
Total equity$1.3B+58.9%
Total assets$1.7B+42.2%

Cash flow

See full
Operating cash flow$100.8M+57.6%
CapEx$5.1M+1,613%
Free cash flow$95.7M+50.3%

Valuation

See full
Market cap$4.9B+23.1%
Enterprise value$4.59B+21.3%
P/E12.9×-5.0×
P/S4.3×+0.4×

Profitability

See full
Gross margin91.1%-0.8pp
Operating margin7.6%-15.7pp
Net margin33.4%+11.6pp
FCF margin18.9%—

Returns & leverage

See full
Return on equity35.7%+2.6pp
Debt / equity0.1×0.0×
Current ratio3.4×+0.5×

Where this comes from

Reported directly by Acadia Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Acadia Pharmaceuticals’s 10-Q, filed August 5, 2026.

Filed
Aug 4, 2026, 8:00 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-333243
Line itemThree Months Ended June 30, 2026Three Months Ended June 30, 2025Six Months Ended June 30, 2026Six Months Ended June 30, 2025
NUPLAZID net revenue$183,132$168,479$350,056$328,199
DAYBUE products net revenue124,82796,087225,965180,683
Total revenues307,959264,566576,021508,882
Less:
Cost of product sales12,7858,38424,44917,595
License fees and royalties15,53112,35028,65823,531
Research and development expense:
External research and development55,39554,319104,218109,304

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Acadia Pharmaceuticals's daybue — revenue?
Acadia Pharmaceuticals (ACAD) reported daybue — revenue of $124.83M in Q2 2026.
How has Acadia Pharmaceuticals's daybue — revenue changed year-over-year?
Acadia Pharmaceuticals's daybue — revenue increased by 29.9% year-over-year, from $96.09M to $124.83M.
What does daybue — revenue mean?
This metric represents the total net sales generated from the commercialization of the Daybue product, excluding any taxes collected on behalf of government authorities. It serves as a primary indicator of the product's market adoption, commercial traction, and contribution to the company's overall top-line growth within the central nervous system disorder therapeutic market. Tracking this revenue stream allows investors to evaluate the successful execution of the product launch and its ongoing performance against competitive alternatives.

Ask your AI about Acadia Pharmaceuticals's daybue — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude